Pierrel S.p.A.

BIT:PRL Rapport sur les actions

Capitalisation boursière : €95.9m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Pierrel Résultats passés

Passé contrôle des critères 4/6

Pierrel has been growing earnings at an average annual rate of 7.3%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 4.4% per year. Pierrel's return on equity is 12.1%, and it has net margins of 11.5%.

Informations clés

7.3%

Taux de croissance des bénéfices

-17.0%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie12.4%
Taux de croissance des recettes4.4%
Rendement des fonds propres12.1%
Marge nette11.5%
Dernière mise à jour des bénéfices30 Jun 2023

Mises à jour récentes des performances passées

Recent updates

We Think Pierrel (BIT:PRL) Can Stay On Top Of Its Debt

May 26
We Think Pierrel (BIT:PRL) Can Stay On Top Of Its Debt

Does Pierrel (BIT:PRL) Have A Healthy Balance Sheet?

Aug 11
Does Pierrel (BIT:PRL) Have A Healthy Balance Sheet?

Here's Why Pierrel (BIT:PRL) Has A Meaningful Debt Burden

Apr 05
Here's Why Pierrel (BIT:PRL) Has A Meaningful Debt Burden

Introducing Pierrel (BIT:PRL), A Stock That Climbed 76% In The Last Year

Mar 10
Introducing Pierrel (BIT:PRL), A Stock That Climbed 76% In The Last Year

Calculating The Fair Value Of Pierrel S.p.A. (BIT:PRL)

Feb 10
Calculating The Fair Value Of Pierrel S.p.A. (BIT:PRL)

How Is Pierrel's (BIT:PRL) CEO Paid Relative To Peers?

Dec 30
How Is Pierrel's (BIT:PRL) CEO Paid Relative To Peers?

These 4 Measures Indicate That Pierrel (BIT:PRL) Is Using Debt Extensively

Dec 01
These 4 Measures Indicate That Pierrel (BIT:PRL) Is Using Debt Extensively

Ventilation des recettes et des dépenses

Comment Pierrel gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

BIT:PRL Recettes, dépenses et bénéfices (EUR Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 2327370
31 Mar 2325170
31 Dec 2224170
30 Sep 2225170
30 Jun 2224270
31 Mar 2223370
31 Dec 2124370
30 Sep 2121360
30 Jun 2119160
31 Mar 2121360
31 Dec 2018260
30 Sep 2020360
30 Jun 2023460
31 Mar 2021260
31 Dec 1922260
30 Sep 1922160
30 Jun 1921160
31 Mar 1921160
31 Dec 1820160
30 Sep 1821260
30 Jun 1820260
31 Mar 1819050
31 Dec 1717-350
30 Sep 1715-850
30 Jun 1714-950
31 Mar 1714-850
31 Dec 1615-650
30 Sep 1614-260
30 Jun 1614-160
31 Mar 1615060
31 Dec 1516060
30 Sep 15510-20
30 Jun 158600
31 Mar 1513030
31 Dec 1415-260
30 Sep 1430-16170
30 Jun 1429-16170
31 Mar 1429-12170
31 Dec 1330-13170
30 Sep 1330-14180
30 Jun 1336-12180
31 Mar 1340-13190

Des revenus de qualité: PRL has a large one-off gain of €741.2K impacting its last 12 months of financial results to 30th June, 2023.

Augmentation de la marge bénéficiaire: PRL's current net profit margins (11.5%) are higher than last year (7.5%).


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: PRL has become profitable over the past 5 years, growing earnings by 7.3% per year.

Accélération de la croissance: PRL's earnings growth over the past year (75.3%) exceeds its 5-year average (7.3% per year).

Bénéfices par rapport au secteur d'activité: PRL earnings growth over the past year (75.3%) exceeded the Pharmaceuticals industry 3.7%.


Rendement des fonds propres

ROE élevé: PRL's Return on Equity (12.1%) is considered low.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé